Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
JW Holdings Corporation is a leading player in the specialty and generic drug manufacturing sector, primarily focused on the South Korean market but also expanding its footprint in Asia. The company differentiates itself through a robust pipeline of biosimilars and a strong distribution network, which enhances its competitive position.
JW Holdings generates revenue through the sale of specialty pharmaceuticals and generics, leveraging its strong R&D capabilities to develop competitive biosimilars. The company benefits from pricing power due to its established brand reputation and regulatory approvals, allowing it to maintain healthy gross margins.
Approval of new biosimilars in South Korea and Asia
Changes in healthcare regulations impacting drug pricing
Market share shifts in the generic drug segment
Partnerships or collaborations with global pharmaceutical companies
Regulatory changes affecting drug approval processes
Technological disruption in drug manufacturing
Intensifying competition from both local and international generic manufacturers
Potential for price erosion in the generic drug market
High debt-to-equity ratio (1.35) could limit financial flexibility
Potential liquidity issues given a current ratio of 0.73
moderate - The company's performance is somewhat linked to GDP growth and consumer spending, as healthcare expenditures typically rise in a growing economy.
Interest rates affect JW Holdings primarily through the cost of financing for R&D and capital expenditures. Higher rates could compress margins and reduce investment in new product development.
minimal - The company does not heavily rely on credit for operations, although higher debt levels could impact its financial flexibility.
growth - Investors are likely attracted to JW Holdings for its potential in biosimilars and specialty drugs.
moderate - The stock has exhibited volatility, reflected in a recent 3-month return of -14.4%.